Introduction. {#S1}
=============

Effective and accessible mass testing can help to limit the spread of the current SARS-CoV-2 pandemic. While serology testing reveals recent and past exposure, RNA testing allows early detection of active infection. Standard RT-qPCR^[@R1]^ and relatives^[@R2]--[@R10]^ achieve high analytical sensitivity (1--100 copies of viral RNA per input μl)^[@R11]^, but take hours and require relatively complex equipment. New sequencing approaches promise high multiplexing but slow response further^[@R12]--[@R15]^. In contrast, isothermal methods such as Recombinase Polymerase Amplification (RPA)^[@R16]--[@R22]^, Recombinase-Aided Amplification (RAA)^[@R23]^, Nicking Enzyme Amplification Reaction (NEAR)^[@R24]^, Loop-mediated isothermal Amplification (LAMP)^[@R25]--[@R39]^, and Rapid Amplification (RAMP, an RPA + LAMP combination)^[@R25]^ typically detect 10--1000 copies of RNA per reaction with minimal or no instrumentation (see review^[@R40]^). The RPA reaction can generate double-stranded DNA (dsDNA) amplicons particularly quickly, but its recombinase-driven priming process is prone to multi-base mismatching that necessitates an additional specificity check^[@R39],[@R41]^. Augmentation of RPA with conditionally extensible primers or cleavable inter-primer probes enhances specificity^[@R16],[@R42],[@R43]^, but tends to reduce reaction speed. Alternatively, Cas12^[@R34]^ or Cas13^[@R19],[@R44]^ nucleases applied to amplification products generate signal in a sequence specific manner, but incur substantial increases in workflow complexity and reaction time. Here, we describe "single-strand RPA" (ssRPA) method, which applies (1) rapid amplification of dsDNA, (2) conversion to ssDNA, and (3) sequence-specific, hybridization-based readout, arranged to maintain both optimal speed and accuracy ([Fig. 1a](#F1){ref-type="fig"}). For amplification, we apply basic RT-RPA^[@R16]^ in the absence of any specificity-enhancing components that may inhibit speed. For ssDNA conversion, we use an exonuclease to digest strands except those chemically protected. Finally, hybridization-based readout is shown with LFDs.

Results. {#S2}
========

We selected the 5′ end of the SARS-CoV-2 spike protein sequence as our main detection target. Per the detailed protocol of [Fig. 1b](#F1){ref-type="fig"} (and Supplementary Protocol), we diluted the sample in a basic RT-RPA reaction mixture, modifying the forward primer with a 5′ tail of 6 phosphorothioate-linked bases to confer exonuclease protection^[@R45],[@R46]^. The reaction was run for 5 min at 42°C on a heating block. A sample of the product was then treated with sodium dodecyl sulfate (SDS) and diluted into an exonuclease and lateral flow (exo/LFD) buffer, where the unprotected strand in the dsDNA was rapidly (≤ 1 min) digested by a T7 exonuclease to yield the protected ssDNA target^[@R45],[@R46]^. A pair of 3′-biotin and 5′-FAM modified probes in the digestion buffer were available to target sequences in between the amplification priming domains, providing specificity not achievable with RPA priming alone. The correct target ssDNA therefore acted as a bridge that co-localized both detection probes within an LFD, ultimately binding gold nanoparticles to the biotin-ligand test line to produce visual readout as early as 1--2 minutes. Full amplification and detection timelines are described in [Fig. 1c](#F1){ref-type="fig"}.

We first tested ssRPA on buffer-spiked samples. [Figure 1d](#F1){ref-type="fig"} (and [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}) shows LFD detection of synthetic SARS-CoV-2 full genome standard serially diluted in DNase/RNase-free water, photographed at multiple intervals on the same strips. Concentrations of input RNA were quantified by RT-qPCR and direct comparison to spectrophotometrically-quantified synthetic standards ([Fig. S2](#SD1){ref-type="supplementary-material"}). Results show detection of 8 copies per 50 μL reaction by naked eye within 8 min (2 min LFD), or 4 copies within 10 min (4 min LFD), and a dynamic range of at least 5 orders of magnitude No test line signal formed for the no-template negative controls over \>60 min of LFD incubation. To test for assay reliability, we spiked 5 μL human saliva with 8 copies of cultured, heat-inactivated virus and showed 20 of 20 positive tests within 8 min ([Figs. 1e](#F1){ref-type="fig"} and [S3](#SD1){ref-type="supplementary-material"}). To test for specificity, we performed ssRPA on water spiked with viral RNA from 8 other respiratory viruses, including genomically similar coronaviruses and alternative diagnoses, each at \>10^5^ copies per assay. None exhibited false positive signals ([Figs. 1f](#F1){ref-type="fig"} and [S4](#SD1){ref-type="supplementary-material"}). Finally, we performed a blinded assay on clinical samples, with a technician unaware of patient type or qPCR result correctly identifying the type (positive or negative) of all 18 samples at 2 min LFD time. Nasopharyngeal (NP) swabs stored in viral transport media (VTM), NP swabs stored in water, and saliva samples were processed by single-tube RNA extraction (1:1 mixture with extraction buffer, 95 °C × 2 min)^[@R47]^ and used at 10% v/v in RT-RPA ([Figs. 1g](#F1){ref-type="fig"} and [S5](#SD1){ref-type="supplementary-material"}). All clinical samples were also semi-quantified by RT-qPCR, using column extraction/concentration and CDC N2 primers ([Fig. 1g](#F1){ref-type="fig"}, [S7](#SD1){ref-type="supplementary-material"}). Results of this limited study demonstrate 100% sensitivity and 100% specificity across all sample types, including NP swabs in water and saliva samples with lower titers (high C~t~).

Discussion. {#S3}
===========

The ssRPA method combines the speed of established RT-RPA^[@R16]^ with the sequence specificity of ssDNA hybridization by serially applying RPA and exonuclease steps. It enables best-in-class performance on the principal axes of reaction time and sensitivity, enabling the detection of 8 copies in 8 min or 4 copies in 10 min. The conceptual framework could be generalized to other isothermal readout methods with dsDNA output for achieving optimal sensitivity and speed. The present method may also be further developed to achieve single-nucleotide specificity, for example by using toehold probe readout^[@R19]^, and spatial multiplexing readout on LFDs with multiple test positions. We also expect future development, including simplified workflow and use of lyophilized reagents for ambient distribution and storage, will further facilitate mass testing.
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![ssRPA assay design, workflow, and characterization.\
**(a)** Key to ssRPA design is the rapid generation of many ssDNA copies from a single RNA target. ssDNA output offers straightforward specific readout by fluorescence or colorimetric/visual methods such as lateral flow devices. **(b)** Step 1: Target viral RNA region (of domains *a-b-c-d*) is reverse transcribed into cDNA via extension of the reverse primer (*d\**) by the Reverse Transcriptase in the reaction mixture^[@R48]^. Subsequently, the cDNA is amplified via isothermal RPA at 42 °C by templated extension of the forward (*a*) and reverse primers (*d\**). The forward primer has a 6-nucleotide long poly-T segment with phosphorothioate bonds. Step 2a: Products of RPA are amended with SDS and transferred to the exo/LFD buffer that contains T7 exonuclease (a dsDNA-specific 5′ to 3′ exonuclease) and detection probes. The resulting mixture is incubated for 1 min at ambient temperature and reverse strand of the dsDNA amplicon products get preferentially digested yielding ssDNA amplicon (*a-b-c-d*) homologous to the target RNA sequence. Step 2b: The 3′ biotin (*b\**) and 5′ FAM (*c\**) modified detection probes, already added, hybridize to target sequences. These probes make the assay directly compatible with commercially available test strips that feature a biotin-binding test line and gold nanoparticles conjugated to rabbit anti-FAM IgG on the conjugate pad. Step 3: The test strip is vertically inserted into the resulting 100 μl mixture. The right ssDNA amplicon acts as a bridge that binds both the biotin-probe and the FAM-probe independently resulting in immobilization of the complex at the test line, where formation of a colored line indicates a positive result. The control line formed of rabbit secondary antibodies captures the remaining gold nanoparticle conjugates by binding to rabbit anti-FAM IgG. **(c)** Timeline of the assay shows the incubation conditions and duration of the 3 main steps in ssRPA: (1) RT-RPA, (2) exonuclease digestion and (3) lateral flow. The test line and control line can be visualized as early as 1--2 min or as late as 60^+^ min without false positives. **(d)** Sensitivity of ssRPA-LFD demonstrated by serial dilution of synthetic SARS-CoV-2 full genome standard (Twist) from \~ 1,000,000 copies down to \~ 2 copies per reaction. A 5 μl volume of genomic viral RNA in DNase/RNase-free water was used as input for a 50 μl reaction volume. After RT-RPA for 5 minutes at 42 °C, 8 μl product was mixed with 12 μl of 10% SDS and then transferred into 80 μl of exo/LFD buffer. Following 1 min T7 exonuclease digestion at room temperature, samples were applied to commercial HybriDetect strips for ≥ 1 min. A time series for the same strip is shown in each column. Note the zero test line signal in negative controls, even at 60 min. **(e)** Using the same procedure as in (d), but spiking 8 copies cultured, heat inactivated SARS-CoV-2 virus (BEI) into 5 μl of SARS-CoV-2-negative human saliva in 20 repeats. No-template negative controls are also shown. (**f**) Specificity was shown by testing 8 other respiratory virus genomic samples, including genomically similar coronaviruses 229E, MERS, (2003) SARS-CoV, and NL63, and alternative diagnoses of influenza B, influenza A, respiratory syncytial virus (RSV), and rhinovirus 17, each at \>10^5^ copies per assay and spiked in DNase/RNase-free water. A sample with virus-derived SARS-CoV-2 RNA at low copy is shown as a positive control. Strips show the readout at 10 min of lateral flow. **(g)** Clinical samples were taken as NP swabs in VTM, NP swabs in water, or saliva, from SARS-CoV-2 positive and negative patients alike, and heat inactivated at vendor for safety. Sample order was randomized prior to ssRPA, and technician was blinded as to patient type or qPCR status to avoid experimental bias. During assay, samples further underwent a 2 min extraction protocol with Lucigen DNA extraction buffer at 50% dilution and 95 °C, and were tested at 10% v/v into ssRPA for 5′ spike targets (see [Methods](#SD1){ref-type="supplementary-material"}). Non-extracted samples yielded little or no signal ([Fig. S6](#SD1){ref-type="supplementary-material"}). Presumptive diagnosis from supplier testing is noted. Concomitant qPCR quantification in our lab, using CDC N2 primers from buffer-exchanged samples, is shown with each result (See also [Fig. S7](#SD1){ref-type="supplementary-material"}).](nihpp-2020.08.17.20177006-f0001){#F1}
